Related Experiment Video
Updated: Jun 9, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.9K
CBD's potential impact on Parkinson's disease: An updated overview
El Ghachi Hafida1, Soulimani Rachid2, Gamrani Halima1
1Neurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco.
Open Medicine (Warsaw, Poland)
|October 31, 2024
Summary
Cannabidiol (CBD) shows promise for Parkinson's disease (PD) symptoms in early research. However, more clinical trials are needed to confirm CBD's effectiveness for both motor and non-motor aspects of PD.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) presents significant motor and non-motor symptoms impacting quality of life.
- Current treatments like l-DOPA have limitations and side effects, necessitating alternative therapies.
- Cannabidiol (CBD), a non-psychoactive cannabis compound, is being investigated for its therapeutic potential.
Purpose of the Study:
- To review the efficacy of CBD in managing both motor and non-motor symptoms of Parkinson's disease.
- To consolidate findings from preclinical studies and clinical trials on CBD for PD.
Main Methods:
- Systematic review of preclinical animal studies.
- Analysis of available clinical trial data on CBD in Parkinson's disease patients.
Main Results:
- Preclinical studies indicate potential benefits of CBD for PD.
- A limited number of clinical trials (seven) exist, hindering definitive conclusions on efficacy.
- Data on CBD's impact on both motor and non-motor symptoms is still emerging.
Conclusions:
- CBD demonstrates therapeutic promise for Parkinson's disease based on preclinical evidence.
- Further extensive clinical research is crucial to validate CBD's efficacy and safety in PD patients.
- Identifying research gaps is essential for future studies on CBD's role in treating PD symptoms.
Related Concept Videos
Parkinson's Disease: Overview
483
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
483
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
163
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
163

